



WO 2003076420




WO 2004022528

(see also Hashimoto K., Recent Patents on CNS Drug Discovery, 2006, 1, 43–53; Harsing L.G. et al., Current Medicinal Chemistry, 2006, 13, 1017–1044; Javitt D.C., Molecular Psychiatry (2004) 9, 984–997; Lindsley, C.W. et al., Current Topics in Medicinal Chemistry, 2006, 6, 771–785; Lindsley C.W. et al., Current Topics in Medicinal Chemistry, 2006, 6, 1883–1896).

It was one object of the present invention to provide further glycine transporter inhibitors.

Summary Of The ~~Invention~~Disclosure

The present ~~invention~~disclosure relates to heterocyclic compounds of the formula (I)



(I)

wherein

R^{13a}, R^{13b}


together are carbonyl or optionally substituted alkylene, wherein one -CH_2- of alkylene may be replaced by an oxygen atom or -NR^{15}-;

R^{14} is hydrogen or alkyl;

R^{15} is hydrogen or alkyl; and

or a physiologically tolerated salt thereof.


Thus, the present ~~invention~~disclosure relates to heterocyclic compounds having the formula (Ia)



(Ia)

wherein A, R^1, W, A^1, Q, Y, A^2, X^1, R^2, R^3, R^4, X^2, X^3, R^5, n are as defined herein.

Fruther, the present ~~invention~~disclosure relates to heterocyclic compounds of formula (I) wherein R is –CN, i.e. heterocyclic compounds having the formula (Ib)



(Ib)

wherein A, R^2, R^3, R^4, X^2, X^3, R^5, n are as defined herein.

Thus, the term heterocyclic compound is used herein to denote in particular tetrahydropyridines (n=1) fused to 5- or 6-membered heterocyclic ring as well as homologous bicyclic compounds wherein n is 0 or 2.

Said compounds of formula (I), i.e., the heterocyclic compounds of formula (I) and their physiologically tolerated acid addition salts, are glycine transporter inhibitors and thus useful as pharmaceuticals.

The present ~~invention~~disclosure thus further relates to the compounds of formula (I) for use in therapy.

The present ~~invention~~disclosure also relates to pharmaceutical compositions which comprise a carrier and a compound of formula (I).

In particular, said compounds, i.e., the heterocyclic compounds and their physiologically tolerated acid addition salts, are inhibitors of the glycine transporter GlyT1.

The present ~~invention~~disclosure thus further relates to the compounds of formula (I) for use in inhibiting the glycine transporter.

The present ~~invention~~disclosure also relates to the use of the compounds of formula (I) in the manufacture of a medicament for inhibiting the glycine transporter GlyT1 and corresponding methods of inhibiting the glycine transporter GlyT1.

Glycine transport inhibitors and in particular inhibitors of the glycine transporter GlyT1 are known to be useful in treating a variety of neurologic and psychiatric disorders.

The present ~~invention~~disclosure thus further relates to the compounds of formula (I) for use in treating a neurologic or psychiatric disorder.

The present ~~invention~~disclosure further relates to the compounds for formula(I) for use in treating pain.


The present ~~invention~~disclosure also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating a neurologic or psychiatric disorder and corresponding methods of treating said disorders. The present ~~invention~~disclosure also relates to the use of the compounds of formula (I) in the manufacture of a medicament for treating pain and corresponding methods of treating pain.

Detailed Description Of The Invention

Provided that the heterocyclic compounds of the formula (I) of a given constitution may exist in different spatial arrangements, for example if they possess one or more centers of

We claim:

1. Heterocyclic compounds of the formula (I)



(I)

wherein

A is a 5- or 6-membered heterocyclic ring;

R is R^1-W-A^1-Q-Y-A^2-X^1-;

R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_1-C_6-alkylcarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkyloxycarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylsulfonylamino-C_1-C_4-alkyl, (optionally substituted C_6-C_{12}-aryl-C_1-C_6-alkyl)amino-C_1-C_4-alkyl, optionally substituted C_6-C_{12}-aryl-C_1-C_4-alkyl, optionally substituted C_3-C_{12}-heterocyclyl-C_1-C_4-alkyl, C_3-C_{12}-cycloalkyl, C_1-C_6-alkylcarbonyl, C_1-C_6-alkoxycarbonyl, halogenated C_1-C_6-alkoxycarbonyl, C_6-C_{12}-aryloxycarbonyl, aminocarbonyl, C_1-C_6-alkylaminocarbonyl, (halogenated C_1-C_4-alkyl)aminocarbonyl, C_6-C_{12}-arylaminocarbonyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkoxy, halogenated C_1-C_6-alkoxy, C_1-C_6-hydroxyalkoxy, C_1-C_6-alkoxy-C_1-C_4-alkoxy, amino-C_1-C_4-alkoxy, C_1-C_6-alkylamino-C_1-C_4-alkoxy, di-C_1-C_6-alkylamino-C_1-C_4-alkoxy, C_1-C_6-alkylcarbonylamino-C_1-C_4-alkoxy, C_6-C_{12}-arylcarbonylamino-C_1-C_4-alkoxy, C_1-C_6-alkoxycarbonylamino-C_1-C_4-alkoxy, C_6-C_{12}-aryl-C_1-C_4-alkoxy, C_1-C_6-alkylsulfonylamino-C_1-C_4-alkoxy, (halogenated C_1-C_6-alkyl)sulfonylamino-C_1-C_4-alkoxy, C_6-C_{12}-arylsulfonylamino-C_1-C_4-alkoxy, (C_6-C_{12}-aryl-C_1-C_6-alkyl)sulfonylamino-C_1-C_4-alkoxy, C_3-C_{12}-heterocyclylsulfonylamino-C_1-

C_4-alkoxy, C_3-C_{12}-heterocyclyl-C_1-C_4-alkoxy, C_6-C_{12}-aryloxy, C_3-C_{12}-heterocyclyloxy, C_1-C_6-alkylthio, halogenated C_1-C_6-alkylthio, C_1-C_6-alkylamino, (halogenated C_1-C_6-alkyl)amino, di-C_1-C_6-alkylamino, di-(halogenated C_1-C_6-alkyl)amino, C_1-C_6-alkylcarbonylamino, (halogenated C_1-C_6-alkyl)carbonylamino, C_6-C_{12}-arylcarbonylamino, C_1-C_6-alkylsulfonylamino, (halogenated C_1-C_6-alkyl)sulfonylamino, C_6-C_{12}-arylsulfonylamino or optionally substituted C_3-C_{12}-heterocyclyl;

W is $-NR^8-$ or a bond;

A^1 is optionally substituted C_1-C_4-alkylene or a bond;

Q is $-S(O)_2-$, $-C(O)-$ or a bond;

Y is $-NR^9-$ or a bond;

A^2 is optionally substituted C_1-C_4-alkylene, C_1-C_4-alkylene-CO-, -CO-C_1-C_4-alkylene, C_1-C_4-alkylene-O-C_1-C_4-alkylene, C_1-C_4-alkylene-NR^{10}-C_1-C_4-alkylene, optionally substituted C_2-C_4-alkenylen, optionally substituted C_2-C_4-alkynylene, optionally substituted C_6-C_{12}-arylene, optionally substituted C_6-C_{12}-heteroarylene or a bond;

X^1 is -O-, $-NR^{11}-$, -S-, optionally substituted C_1-C_4-alkylene, optionally substituted C_2-C_4-alkenylen, optionally substituted C_2-C_4-alkynylene or a bond,

with the proviso that if Q is a bond, W is $-NR^8-$ or Y is $-NR^9-$;

R^2 is hydrogen, halogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, -CN, C_2-C_6-alkenyl, C_2-C_6-alkynyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkoxy, halogenated C_1-C_6-alkoxy, C_1-C_6-alkoxycarbonyl, C_2-C_6-alkenyloxy, C_6-C_{12}-aryl-C_1-C_4-alkoxy, C_1-C_6-alkylcarbonyloxy, C_1-C_6-alkylthio, C_1-C_6-alkylsulfinyl, C_1-C_6-alkylsulfonyl, aminosulfonyl, amino, C_1-C_6-alkylamino, C_2-C_6-alkenylamino, nitro or optionally substituted C_3-C_{12}-heterocyclyl, or two radicals R^2 together with the ring atoms of A to which they are bound form an optionally substituted 5- or 6-membered ring;

R^3 is hydrogen, halogen, C_1-C_6-alkyl or C_1-C_6-alkoxy, or two radicals R^3 together with the carbon atom to which they are attached form a carbonyl group;

R^4 is hydrogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, CH_2CN, -CHO, C_1-C_4-alkylcarbonyl, (halogenated C_1-C_4-alkyl)carbonyl, C_1-C_4-alkoxycarbonyl, C_6-C_{12}-arylcarbonyl, C_1-C_6-alkylaminocarbonyl, C_2-C_6-alkenyl, -C(=NH)NH_2, -C(=NH)NHCN, C_1-C_6-alkylsulfonyl, C_6-C_{12}-arylsulfonyl, amino or C_3-C_{12}-heterocyclyl;

X^2 is -O-, -NR^6-, -S-, >$CR^{12a}R^{12b}$ or a bond;

X^3 is -O-, -NR^7-, -S-, >$CR^{13a}R^{13b}$ or a bond;

R^5 is optionally substituted C_6-C_{12}-aryl, optionally substituted C_3-C_{12}-cycloalkyl or optionally substituted C_3-C_{12}-heterocyclyl;

n is 0, 1, 2;

R^6 is hydrogen or C_1-C_6-alkyl;

R^7 is hydrogen or C_1-C_6-alkyl;

R^8 is hydrogen or C_1-C_6-alkyl;

R^9 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl, amino-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl-C_1-C_4-alkyl or C_3-C_{12}-heterocyclyl; or

R^9, R^1

together are C_1-C_4-alkylene; or

R^9 is C_1-C_4-alkylene that is bound to a carbon atom in A^2 and A^2 is C_1-C_4-alkylene or to a carbon atom in X^1 and X^1 is C_1-C_4-alkylene;

R^{10} is hydrogen, C_1-C_6-alkyl or C_1-C_6-alkylsulfonyl;

R^{11} is hydrogen or C_1-C_6-alkyl, or

R^9, R^{11}
together are C_1-C_4-alkylene,

R^{12a} is hydrogen, optionally substituted C_1-C_6-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_3-C_{12}-heterocyclyl-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl or hydroxy;

R^{12b} is hydrogen or C_1-C_6-alkyl, or

R^{12a}, R^{12b}
together are carbonyl or optionally substituted C_1-C_4-alkylene, wherein one $-CH_2-$ of C_1-C_4-alkylene may be replaced by an oxygen atom or $-NR^{14}-$;

R^{13a} is hydrogen, optionally substituted C_1-C_6-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_3-C_{12}-heterocyclyl-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl or hydroxy;

R^{13b} is hydrogen or C_1-C_6-alkyl, or


R^{13a}, R^{13b}
together are carbonyl or optionally substituted C_1-C_4-alkylene, wherein one $-CH_2-$ of C_1-C_4-alkylene may be replaced by an oxygen atom or $-NR^{15}-$;


R^{14} is hydrogen or C_1-C_6-alkyl;

R^{15} is hydrogen or C_1-C_6-alkyl; and

or a physiologically tolerated salt thereof.

2. Compound as claimed in claim 1, wherein A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:



and 

3. Compound as claimed in claim 1 or 2, wherein -Y-A^2-X^1- comprises at least 2, 3 or 4 atoms in the main chain.

4. Compound as claimed in any one of claims 1 to 3, wherein R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_1-C_6-alkyloxycarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, C_6-C_{12}-aryl-C_1-C_4-alkyl, C_3-C_{12}-cycloalkyl, C_2-C_6-alkenyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkylamino, (halogenated C_1-C_6-alkyl)amino, di-C_1-C_6-alkylamino or optionally substituted C_3-C_{12}-heterocyclyl.

5. Compound as claimed in any one of claims 1 to 4, wherein W is -NR^8- and Y is a bond; W is a bond and Y is –NR^9-; or W is a bond, Q is a bond and Y is–NR^9-.

6. Compound as claimed in any one of claims 1 to 5, wherein A^1 is a bond.

7. Compound as claimed in any one of claims 1 to 5, wherein A^1 is C_1-C_4-alkylene and W is -NR^8-.

8. Compound as claimed in any one of claims 1 to 7, wherein A^2 is optionally substituted C_1-C_4-alkylene.

9. Compound as claimed in any one of claims 1 to 7, wherein A^2 is C_1-C_4-alkylene.

10. Compound as claimed in any one of claims 1 to 7, wherein A^2 is C_6-C_{12}-arylene selected from the group consisting of phen-1,4-ylene and phen-1,3-ylene, or C_6-C_{12}-heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4-ylene.


11. Compound as claimed in any one of claims 1 to 10, wherein X^1 is -O- or -NR^{11}, or X^1 is optionally substituted C_1-C_4-alkylene and A^2 is a bond.

12. Compound as claimed in any one of claims 1 to 10, wherein X^1 is a bond.

13. Compound as claimed in claim 12, wherein -Y-A^2-X^1- is -NR^9-C_1-C_4-alkylene-.

14. Compound as claimed in any one of claims 1 to 13, wherein R^1-W-A^1-Q-Y-A^2-X^1- is R^1-$S(O)_2$-NH-A^2-X^1-, R^1-NH-$S(O)_2$-A^2-X^1-, R^1-C(O)-NH-A^2-X^1-, R^1-NH-C(O)-A^2-X^1- or R^1-NH-A^2-X^1-.

15. Compound as claimed in any one of claims 1 to 14, having one of the formulae




wherein R^1, W, A^1, Q, Y, A^2, X^1, R^2, R^3, R^4, X^2, X^3, R^5, n are as defined in any one of claims 1 to 15.

16. Compound as claimed in any one of claims 1 to 15, wherein R^2 is hydrogen, halogen or C_1-C_6-alkoxy.

17. Compound as claimed in any one of claims 1 to 16, wherein R^3 is hydrogen or C_1-C_6-alkyl.

18. Compound as claimed in any one of claims 1 to 17, having the formula



wherein R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e} independently have the meaning of R^3, and A, R, R^2, R^3, R^4, X^2, X^3, R^5, n are as defined in any one of claims 1 to 17.

19. Compound as claimed in any one of claims 1 to 18, wherein R^4 is hydrogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, amino-C_1-C_4-alkyl, CH_2CN, C_1-C_4-alkylcarbonyl, (halogenated C_1-C_4-alkyl)carbonyl, C_1-C_4-alkoxycarbonyl, -C(=NH)NH_2, -C(=NH)NHCN, C_1-C_6-alkylsulfonyl, amino or C_3-C_{12}-heterocyclyl.

20. Compound as claimed in any one of claims 1 to 19, wherein X^2 is $>CR^{12a}R^{12b}$.

21. Compound as claimed in any one of claims 1 to 20, wherein X^3 is a bond.

22. Compound as claimed in any one of claims 1 to 21, wherein R^{12a} is hydrogen and R^{12b} is hydrogen.


23. Compound as claimed in any one of claims 1 to 21, wherein R^{12a} is C_1-C_6-alkyl and R^{12b} is hydrogen or C_1-C_6-alkyl.

24. Compound as claimed in any one of claims 1 to 21, wherein R^{12a}, R^{12b} together are optionally substituted C_1-C_4-alkylene.

25. Compound as claimed in claim 24, wherein optionally substituted C_1-C_4-alkylene is optionally substituted 1,3-propylene.

26. Compound as claimed in any one of claims 1 to 25, wherein R^5 is optionally substituted aryl.

27. Compound as claimed in claim 26, having the formula






wherein A, R, R^2, R^3, R^4, X^2, X^3, n are as defined in any one of claims 1 to 26; and R^{15a}, R^{15b}, R^{15c}, R^{15d}, R^{15e}, R^{15f} independently are hydrogen, halogen, optionally substituted C_1-C_6-alkyl, halogenated C_1-C_6-alkyl, CN, hydroxy, C_1-C_6-alkoxy, amino, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino or C_3-C_{12}-heterocyclyl.

28. Compound as claimed in any one of claims 1 to 27, wherein R^9 is hydrogen.

29. Compound as claimed in any one of claims 1 to 28, wherein n is 1.

30. Compound as claimed in claim 1, wherein

A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:

  and 

R is R^1-W-A^1-Q-Y-A^2-X^1-;

R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl, optionally substituted C_6-C_{12}-aryl, or optionally substituted C_3-C_{12}-heterocyclyl;

W is a bond;

A^1 is a bond;

Q is -$S(O)_2$-, -C(O)- or a bond;

Y is -NR^9- or a bond;

with the proviso that if Q is a bond, Y is -NR^9-;

A^2 is C_1-C_4-alkylene;

X^1 is a bond;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is hydrogen or C_1-C_4-alkoxycarbonyl;

X^2 is >$CR^{12a}R^{12b}$;

X^3 is a bond;

R^5 is optionally substituted phenyl;





R^9 is hydrogen; and

R^{12a}, R^{12b}

together are optionally substituted C_1-C_4-alkylene.

31. Compound as claimed in claim 1, wherein

A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:



and



R is R^1-W-A^1-Q-Y-A^2-X^1-,

R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl, optionally substituted C_6-C_{12}-aryl, or optionally substituted C_3-C_{12}-heterocyclyl;

W is a bond;

A^1 is a bond;

Q is $-S(O)_2-$, -C(O)- or a bond;

Y is $-NR^9-$ or a bond;

with the proviso that if Q is a bond, Y is $-NR^9-$;

A^2 is C_1-C_4-alkylene;

X^1 is a bond;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is hydrogen or C_1-C_4-alkoxycarbonyl;

X^2 is $>CR^{12a}R^{12b}$;

X^3 is a bond;

R^5 is optionally substituted phenyl;

R^9 is hydrogen or C_3-C_{12}-heterocyclyl; and

R^{12a} is hydrogen;

R^{12b} is hydrogen, or

R^{12a}, R^{12b}

together are optionally substituted C_1-C_4-alkylene.

32. The compound as claimed in any one of claims 1 to 31 for use in therapy.

33. Pharmaceutical composition which comprises a carrier and a compound of any one of claims 1 to 31.

34. The use of an effective amount of a compound of any one of the claims 1 to 31 for inhibiting the glycine transporter GlyT1 in a mammal in need thereof.

35. The use of a compound of any one of claims 1 to 31 in the manufacture of a medicament for inhibiting the glycine transporter GlyT1.

36. The use of a therapeutically effective amount of a compound of any one of claims 1 to 31 for treating a neurologic or psychiatric disorder or pain in a mammalian patient in need thereof.

37. The use of a compound of any one of claims 1 to 31 in the manufacture of a medicament for treating a neurologic or psychiatric disorder or pain.

38. The compound of any one of the claims 1 to 31 for use in the treatment of a neurologic or psychiatric disorder or pain.

39. The use or compound as claimed in any one of claims 34 to 38, wherein the disorder is associated with glycinergic or glutamatergic neurotransmission dysfunction.


40. The use or compound as claimed in any one of claims 34 to 38, wherein the neurologic disorder is a cognitive disorder such as dementia, cognitive impairment, attention deficit disorder.

41. The use or compound as claimed in claim 40, wherein the attention deficit disorder is a the attention deficit disorder with hyperactivity.

42. The use or compound as claimed in any one of claims 34 to 38, wherein the psychiatric disorder is an anxiety disorder, a mood disorder such as depression, a bipolar disorder, schizophrenia, or a psychotic disorder.

We claim:

1. Heterocyclic compounds of the formula (I)



(I)

wherein

A is a 5- or 6-membered heterocyclic ring;

R is R^1-W-A^1-Q-Y-A^2-X^1-;

R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_1-C_6-alkylcarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkyloxycarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylsulfonylamino-C_1-C_4-alkyl, (optionally substituted C_6-C_{12}-aryl-C_1-C_6-alkyl)amino-C_1-C_4-alkyl, optionally substituted C_6-C_{12}-aryl-C_1-C_4-alkyl, optionally substituted C_3-C_{12}-heterocyclyl-C_1-C_4-alkyl, C_3-C_{12}-cycloalkyl, C_1-C_6-alkylcarbonyl, C_1-C_6-alkoxycarbonyl, halogenated C_1-C_6-alkoxycarbonyl, C_6-C_{12}-aryloxycarbonyl, aminocarbonyl, C_1-C_6-alkylaminocarbonyl, (halogenated C_1-C_4-alkyl)aminocarbonyl, C_6-C_{12}-arylaminocarbonyl, C_2-C_6-alkenyl, C_2-C_6-alkynyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkoxy, halogenated C_1-C_6-alkoxy, C_1-C_6-hydroxyalkoxy, C_1-C_6-alkoxy-C_1-C_4-alkoxy, amino-C_1-C_4-alkoxy, C_1-C_6-alkylamino-C_1-C_4-alkoxy, di-C_1-C_6-alkylamino-C_1-C_4-alkoxy, C_1-C_6-alkylcarbonylamino-C_1-C_4-alkoxy, C_6-C_{12}-arylcarbonylamino-C_1-C_4-alkoxy, C_1-C_6-alkoxycarbonylamino-C_1-C_4-alkoxy, C_6-C_{12}-aryl-C_1-C_4-alkoxy, C_1-C_6-alkylsulfonylamino-C_1-C_4-alkoxy, (halogenated C_1-C_6-alkyl)sulfonylamino-C_1-C_4-alkoxy, C_6-C_{12}-arylsulfonylamino-C_1-C_4-alkoxy, (C_6-C_{12}-aryl-C_1-C_6-alkyl)sulfonylamino-C_1-C_4-alkoxy, C_3-C_{12}-heterocyclylsulfonylamino-C_1-C_4-alkoxy, C_3-C_{12}-heterocyclyl-C_1-C_4-alkoxy, C_6-C_{12}-aryloxy, C_3-C_{12}-heterocyclyloxy, C_1-C_6-alkylthio, halogenated C_1-C_6-alkylthio, C_1-C_6-alkylamino, (halogenated C_1-C_6-alkyl)amino, di-C_1-C_6-alkylamino, di-(halogenated C_1-C_6-alkyl)amino, C_1-C_6-alkylcarbonylamino, (halogenated C_1-C_6-alkyl)carbonylamino, C_6-C_{12}-

arylcarbonylamino, C_1-C_6-alkylsulfonylamino, (halogenated C_1-C_6-alkyl)sulfonylamino, C_6-C_{12}-arylsulfonylamino or optionally substituted C_3-C_{12}-heterocyclyl;

W is $-NR^8-$ or a bond;

A^1 is optionally substituted C_1-C_4-alkylene or a bond;

Q is $-S(O)_2-$, -C(O)- or a bond;

Y is $-NR^9-$ or a bond;

A^2 is optionally substituted C_1-C_4-alkylene, C_1-C_4-alkylene-CO-, -CO-C_1-C_4-alkylene, C_1-C_4-alkylene-O-C_1-C_4-alkylene, C_1-C_4-alkylene-NR^{10}-C_1-C_4-alkylene, optionally substituted C_2-C_4-alkenylen, optionally substituted C_2-C_4-alkynylene, optionally substituted C_6-C_{12}-arylene, optionally substituted C_6-C_{12}-heteroarylene or a bond;

X^1 is -O-, $-NR^{11}-$, -S-, optionally substituted C_1-C_4-alkylene, optionally substituted C_2-C_4-alkenylen, optionally substituted C_2-C_4-alkynylene or a bond,

with the proviso that if Q is a bond, W is $-NR^8-$ or Y is $-NR^9-$;

R^2 is hydrogen, halogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, -CN, C_2-C_6-alkenyl, C_2-C_6-alkynyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkoxy, halogenated C_1-C_6-alkoxy, C_1-C_6-alkoxycarbonyl, C_2-C_6-alkenyloxy, C_6-C_{12}-aryl-C_1-C_4-alkoxy, C_1-C_6-alkylcarbonyloxy, C_1-C_6-alkylthio, C_1-C_6-alkylsulfinyl, C_1-C_6-alkylsulfonyl, aminosulfonyl, amino, C_1-C_6-alkylamino, C_2-C_6-alkenylamino, nitro or optionally substituted C_3-C_{12}-heterocyclyl, or two radicals R^2 together with the ring atoms of A to which they are bound form an optionally substituted 5- or 6-membered ring;

R^3 is hydrogen, halogen, C_1-C_6-alkyl or C_1-C_6-alkoxy, or two radicals R^3 together with the carbon atom to which they are attached form a carbonyl group;

R^4 is hydrogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, hydroxy-C_1-C_4-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, CH_2CN, -CHO, C_1-C_4-alkylcarbonyl, (halogenated C_1-C_4-alkyl)carbonyl, C_1-C_4-alkoxycarbonyl, C_6-C_{12}-arylcarbonyl, C_1-C_6-alkylaminocarbonyl, C_2-C_6-alkenyl, $-C(=NH)NH_2$, $-C(=NH)NHCN$, C_1-C_6-alkylsulfonyl, C_6-C_{12}-arylsulfonyl, amino or C_3-C_{12}-heterocyclyl;

X^2 is -O-, -NR^6-, -S-, >$CR^{12a}R^{12b}$ or a bond;

X^3 is -O-, -NR^7-, -S-, >$CR^{13a}R^{13b}$ or a bond;

R^5 is optionally substituted C_6-C_{12}-aryl, optionally substituted C_3-C_{12}-cycloalkyl or optionally substituted C_3-C_{12}-heterocyclyl;

n is 0, 1, 2;

R^6 is hydrogen or C_1-C_6-alkyl;

R^7 is hydrogen or C_1-C_6-alkyl;

R^8 is hydrogen or C_1-C_6-alkyl;

R^9 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl, amino-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl-C_1-C_4-alkyl or C_3-C_{12}-heterocyclyl; or

R^9, R^1
together are C_1-C_4-alkylene; or

R^9 is C_1-C_4-alkylene that is bound to a carbon atom in A^2 and A^2 is C_1-C_4-alkylene or to a carbon atom in X^1 and X^1 is C_1-C_4-alkylene;

R^{10} is hydrogen, C_1-C_6-alkyl or C_1-C_6-alkylsulfonyl;

R^{11} is hydrogen or C_1-C_6-alkyl, or

R^9, R^{11}
together are C_1-C_4-alkylene,

R^{12a} is hydrogen, optionally substituted C_1-C_6-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_3-C_{12}-heterocyclyl-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl or hydroxy;

R^{12b} is hydrogen or C_1-C_6-alkyl, or

R^{12a}, R^{12b}
together are carbonyl or optionally substituted C_1-C_4-alkylene, wherein one -CH_2- of C_1-C_4-alkylene may be replaced by an oxygen atom or -NR^{14}-;

R^{13a} is hydrogen, optionally substituted C_1-C_6-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_3-C_{12}-heterocyclyl-C_1-C_6-alkyl, optionally substituted C_6-C_{12}-aryl or hydroxy;

R^{13b} is hydrogen or C_1-C_6-alkyl, or


R^{13a}, R^{13b}
together are carbonyl or optionally substituted C_1-C_4-alkylene, wherein one $-CH_2-$ of C_1-C_4-alkylene may be replaced by an oxygen atom or $-NR^{15}-$;

R^{14} is hydrogen or C_1-C_6-alkyl;

R^{15} is hydrogen or C_1-C_6-alkyl; and

or a physiologically tolerated salt thereof.

2. Compound as claimed in claim 1, wherein A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:



3. Compound as claimed in claim 1 or 2, wherein -Y-A^2-X^1- comprises at least 2, 3 or 4 atoms in the main chain.

4. Compound as claimed in any one of claims 1 to 3, wherein R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, C_1-C_6-alkoxy-C_1-C_4-alkyl, amino-C_1-C_4-alkyl, C_1-C_6-alkylamino-C_1-C_4-alkyl, di-C_1-C_6-alkylamino-C_1-C_4-alkyl, C_1-C_6-alkyloxycarbonylamino-C_1-C_4-alkyl, C_1-C_6-alkylaminocarbonylamino-C_1-C_4-alkyl, C_6-C_{12}-aryl-C_1-C_4-alkyl, C_3-C_{12}-cycloalkyl, C_2-C_6-alkenyl, optionally substituted C_6-C_{12}-aryl, hydroxy, C_1-C_6-alkylamino, (halogenated C_1-C_6-alkyl)amino, di-C_1-C_6-alkylamino or optionally substituted C_3-C_{12}-heterocyclyl.

5. Compound as claimed in one of claims 1 to 4, wherein A^1 is a bond, or A^1 is C_1-C_4-alkylene and W is $-NR^8$-.


6. Compound as claimed in any one of claims 1 to 5, wherein A^2 is optionally substituted C_1-C_4-alkylene, or A^2 is C_6-C_{12}-arylene selected from the group consisting of phen-1,4-ylene and phen-1,3-ylene, or C_6-C_{12}-heteroarylene selected from the group consisting of pyrid-2,5-ylene and pyrid-2,4-ylene.


7. Compound as claimed in any one of claims 1 to 6, wherein X^1 is -O- or $-NR^{11}$, or X^1 is optionally substituted C_1-C_4-alkylene and A^2 is a bond, or X^1 is a bond.


8. Compound as claimed in claim 7, wherein $-Y-A^2-X^1-$ is $-NR^9-C_1-C_4$-alkylene-.


9. Compound as claimed in any one of claims 1 to 8, wherein R^1-W-A^1-Q-Y-A^2-X^1- is R^1-$S(O)_2$-NH-A^2-X^1-, R^1-NH-$S(O)_2$-A^2-X^1-, R^1-C(O)-NH-A^2-X^1-, R^1-NH-C(O)-A^2-X^1- or R^1-NH-A^2-X^1-.

10. Compound as claimed in one of claims 1 to 9, having one of the formulae









wherein R^1, W, A^1, Q, Y, A^2, X^1, R^2, R^3, R^4, X^2, X^3, R^5, n are as defined in any one of claims 1 to 9.

11. Compound as claimed in any one of claims 1 to 10, wherein R^4 is hydrogen, C_1-C_6-alkyl, halogenated C_1-C_4-alkyl, amino-C_1-C_4-alkyl, CH_2CN, C_1-C_4-alkylcarbonyl, (halogenated C_1-C_4-alkyl)carbonyl, C_1-C_4-alkoxycarbonyl, $-C(=NH)NH_2$, -C(=NH)NHCN, C_1-C_6-alkylsulfonyl, amino or C_3-C_{12}-heterocyclyl.


12. Compound as claimed in any one of claims 1 to 11, wherein X^2 is $>CR^{12a}R^{12b}$, and X^3 is a bond.

13. Compound as claimed in any one of claims 1 to 12, wherein R^{12a} is hydrogen and R^{12b} is hydrogen, or R^{12a} is C_1-C_6-alkyl and R^{12b} is hydrogen or C_1-C_6-alkyl, or R^{12a}, R^{12b} together are optionally substituted C_1-C_4-alkylene such as

optionally substituted 1,3-propylene.

14. Compound as claimed in any one of claims 1 to 13, wherein R^5 is optionally substituted aryl.

15. Compound as claimed in claim 14, having the formula



wherein A, R, R^2, R^3, R^4, X^2, X^3, n are as defined in any one of claims 1 to 14; and





R^{15a}, R^{15b}, R^{15c}, R^{15d}, R^{15e}, R^{15f}

independently are hydrogen, halogen, optionally substituted C_1-C_6-alkyl, halogenated C_1-C_6-alkyl, CN, hydroxy, C_1-C_6-alkoxy, amino, C_1-C_6-alkylamino, di-C_1-C_6-alkylamino or C_3-C_{12}-heterocyclyl.

16. Compound as claimed in any one of claims 1 to 15, wherein n is 1.

17. Compound as claimed in claim 1, wherein

A is a ring selected from the group consisting of the following 5- or 6-membered heterocyclic rings:



and



R is R^1-W-A^1-Q-Y-A^2-X^1-;

R^1 is hydrogen, C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl-C_1-C_4-alkyl, halogenated C_1-C_6-alkyl, C_3-C_{12}-cycloalkyl, optionally substituted C_6-C_{12}-aryl, or optionally substituted C_3-C_{12}-heterocyclyl;

W is a bond;

A^1 is a bond;

Q is -$S(O)_2$-, -C(O)- or a bond;

Y is -NR^9- or a bond;

with the proviso that if Q is a bond, Y is -NR^9-;

A^2 is C_1-C_4-alkylene;

X^1 is a bond;

R^2 is hydrogen;

R^3 is hydrogen;

R^4 is hydrogen or C_1-C_4-alkoxycarbonyl;

X^2 is >$CR^{12a}R^{12b}$;

X^3 is a bond;

R^5 is optionally substituted phenyl;

R^9 is hydrogen or C_3-C_{12}-heterocyclyl; and

R^{12a} is hydrogen;

R^{12b} is hydrogen, or

R^{12a}, R^{12b} together are optionally substituted C_1-C_4-alkylene.

18. Compound as claimed in claim 1, which is:
N-(2-(7-(1-phenylcyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;
N-(Azetidin-3-yl)-N-(2-(7-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)propane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-3-fluoropropane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-1-yl)ethyl)-1-methyl-1H-imidazole-4-sulfonamide;
N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)propane-1-sulfonamide;
N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-cyclopropylmethanesulfonamide;
N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-methyl-1H-pyrazole-4-sulfonamide;
N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-1-methyl-1H-imidazole-4-sulfonamide;
N-((8-(1-(4-Chlorophenyl)cyclobutyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)methyl)-3-fluoropropane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)ethanesulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)methanesulfonamide;

N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)benzenesulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)butane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-methyl-1H-imidazole-4-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-3-fluoropropane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)cyclobutanesulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-1-cyclopropylmethanesulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-2-methylpropane-1-sulfonamide;
N-(2-(7-(1-(4-Chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)pyridine-3-sulfonamide;
N-(2-(7-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-2-yl)ethyl)-N-methylpropane-1-sulfonamide;
N-(2-{1-[1-(4-Chlorophenyl)cyclobutyl]-1,2,3,4-tetrahydro-9H-b-carbolin-9-yl}ethyl)propane-1-sulfonamide;
N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)propane-1-sulfonamide;
N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-pyrazole-4-sulfonamide;
N-(2-(4-(1-(4-chlorophenyl)cyclobutyl)-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-yl)ethyl)-1-methyl-1H-imidazole-4-sulfonamide;
Propane-1-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Propane-1-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
1-Methyl-1H-pyrazole-4-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
1-Methyl-1H-imidazole-4-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
N-{3-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-methanesulfonamide;
Ethanesulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;

Ethanesulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
N-{2-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-methanesulfonamide;
Butane-1-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
N-{2-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-C-cyclopropyl-methanesulfonamide;
2-Methyl-propane-1-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Cyclobutanesulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Propane-2-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
N-{2-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-benzenesulfonamide;
1-Methyl-1H-pyrazole-4-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
1-Methyl-1H-imidazole-4-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Pyridine-2-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Pyridine-3-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Pyridine-4-sulfonic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
Butane-1-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
2-Methyl-propane-1-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
N-{3-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-C-cyclopropyl-methanesulfonamide;
Cyclobutanesulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
Propane-2-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
N-{3-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-benzenesulfonamide;
Pyridine-2-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;

Pyridine-3-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
Pyridine-4-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
1-Methyl-1H-imidazole-4-carboxylic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
1-Methyl-1H-pyrazole-4-carboxylic acid {2-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-ethyl}-amide;
1-Methyl-1H-pyrazole-4-carboxylic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
1-Methyl-1H-imidazole-4-carboxylic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
1-Methyl-1H-pyrazole-4-carboxylic acid (2-{7-[1-(4-chloro-phenyl)-cyclobutyl]-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridin-2-yl}-ethyl)-amide;
Butane-1-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
2-Methyl-propane-1-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
N-{3-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-C-cyclopropyl-methanesulfonamide;
Cyclobutanesulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
Propane-2-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
N-{3-[4-(4-Chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-benzenesulfonamide;
Pyridine-2-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
Pyridine-3-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide;
Pyridine-4-sulfonic acid {3-[4-(4-chloro-benzyl)-4,5,6,7-tetrahydro-thiazolo[4,5-c]pyridin-2-yl]-propyl}-amide,
or a physiologically tolerated salt thereof.

19. Pharmaceutical composition which comprises a carrier and a compound of any one of any one of claims 1 to 18.

20. Use of a compound of any one of claims 1 to 18, or a physiologically tolerated salt thereof in the manufacture of a medicament for treating a neurologic or psychiatric disorder or pain in a mammalian patient in need thereof.